Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
br Conclusion br Experimental NMR spectra were recorded on a
2020-04-02

Conclusion Experimental NMR spectra were recorded on a Jeol spectrometer at either 270 or 400 MHz for 1H spectra and either 68 or 100 MHz for 13C spectra. All chemical shifts are quoted in ppm relative to tetramethylsilane. In the assignment of signals the abbreviation DHN is used for 2,3-dihy
-
Mulan is one of three E ubiquitin ligases
2020-04-02

Mulan is one of three E3 ubiquitin ligases that are present in the mitochondria along with MARCH5/MITOL (membrane associated RING-CH5) and RNF185 [14], [15], [16], [17]. Mulan is a 352-residue polypeptide that crosses the mitochondrial outer membrane (OMM) twice, its amino-terminus, which includes t
-
In addition to cleaving ubiquitins off modified proteins DUB
2020-04-02

In addition to cleaving ubiquitins off modified proteins, DUBs can also cleave between ubiquitin moieties within a polyubiquitin chain to edit the ubiquitin signal. DUBs employ different strategies to recognize polyubiquitin (Figure 1). DUBs that rely only on interactions on the S1 site tend to be 1
-
Enzymatic assay The usual in vitro test for the measure
2020-04-02

Enzymatic assay. The usual in vitro test for the measure of the activity of DbH involves ascorbate as a cosubstrate (e.g., 5mM) and tyramine as a substrate (e.g., 10mM). When using N-aryl-N′-hydroxyguanidines instead of ascorbate, the hydroxylase activity of DbH was measured by HPLC as the amounts o
-
Phosphate Colorimetric Assay Kit br Material and methods br
2020-04-02

Material and methods Results Discussion Isolated Phosphate Colorimetric Assay Kit have several potential advantages over other in-vitro approaches, such as expression of properties similar to their site of origin including the possibility of bidirectional transmembrane transport and exposur
-
SR1078 Acknowledgments We are grateful to Dr Jean Marie
2020-04-02

Acknowledgments We are grateful to Dr. Jean-Marie Bernassau for his leadership in establishing our virtual screening platform and Dr. Julie Bick for protein purification. X-ray data collection for compound 4 was performed by Shamrock Structures at Southeast Regional Collaborative Access Team (SER-C
-
Acanthopanax senticosus Rupr Maxim Harms a nontoxic herb bel
2020-04-02

Acanthopanax senticosus (Rupr. & Maxim.) Harms, a nontoxic herb belongs to the family of Araliaceae, which found in Northeast Asia. A. senticosus traditionally used as a tonic to treat rheumatism, diabetes, and hepatitis [7]. Previous phytochemical and biological investigations found its roots and s
-
In conclusion adipose PGD suppressed the lipolysis by
2020-04-01

In conclusion, adipose PGD2 suppressed the lipolysis by decreasing the intracellular cAMP level through DP2R. Therefore, PGD2 enhanced adipocyte differentiation (lipid accumulation) through both repression of the lipolysis via DP2R and activation of the lipogenesis via PPARγ. Thus, L-PGDS and DP2R a
-
br Clinical trials of CRM inhibitors
2020-04-01

Clinical trials of CRM1 inhibitors KPT-330 clinical trials have been initiated with promising very early results. One trial includes patients with advanced solid tumors whose disease has progressed after at least one prior therapy for metastatic disease (NCT01607905). Another trial includes patie
-
This letter reports an ab initio study
2020-04-01

This letter reports an ab initio study on the X peaks of PES by including the SO effect. The multiplet split energies are calculated with the SO-MCQDPT2 method [21], and the so-called pole strengths are evaluated to simulate the relative intensities. The results are compared with the experimental PE
-
Another example of negative regulation is the
2020-04-01

Another example of negative regulation is the inhibition of the yeast endosome-associated DUB Doa4 by Rfu1 (free ubiquitin chains 1). In a yeast genetics screen, deletion of Rfu1 was serendipitously found to alter global ubiquitin levels [69]. DUBs can regulate these levels by liberating conjugated
-
In the past few years neuroprotection via GLP R activation
2020-04-01

In the past few years, neuroprotection via GLP-1R activation has been shown in several animal models of stroke, Alzheimer\'s, Parkinson\'s, Huntington\'s, ALS and traumatic Trovafloxacin mesylate australia injury. This research field is rapidly growing and several reviews have been recently publish
-
We recently described the benzoxazin
2020-04-01

We recently described the 1,3-benzoxazin-4-one analogue of LY294002 and showed it to have pan-PI3K and DNA-PK activity [2]. We have also reported on the activity of other family members, such as 3 which causes sensitization of lung cancer and colon cancer cells to radiation [11] and 4 (LTUSI122) as
-
Findings from the present study indicate that CRF receptors
2020-04-01

Findings from the present study indicate that CRF1 receptors are especially important in fear acquisition. CP154,526 given before acquisition training, at least partly, reinstated the fear-potentiated startle response and blocked the development of contextual conditioned fear in SERT−/− rats. CP154,
-
On the basis of the findings described above a series
2020-04-01

On the basis of the findings described above, a series of heterotricyclic analogs were designed and synthesized. The human CRF1 receptor binding and antagonist activity data for newly designed heterotricyclic core antagonists 28–33 are described in Table 3. Most of the tricyclic core analogs listed
15377 records 845/1026 page Previous Next First page 上5页 841842843844845 下5页 Last page